Characterization of a SARS-CoV-2 EG. 5.1 clinical isolate in vitro and in vivo
R Uraki, M Kiso, K Iwatsuki-Horimoto, S Yamayoshi… - Cell Reports, 2023 - cell.com
Summary EG. 5.1 is a subvariant of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) Omicron XBB variant that is rapidly increasing in prevalence worldwide …
(SARS-CoV-2) Omicron XBB variant that is rapidly increasing in prevalence worldwide …
Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination
The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
highlights the importance of determining the breadth and durability of humoral immunity to …
highlights the importance of determining the breadth and durability of humoral immunity to …
Overview of neutralization assays and international standard for detecting SARS-CoV-2 neutralizing antibody
KT Liu, YJ Han, GH Wu, KYA Huang, PN Huang - Viruses, 2022 - mdpi.com
We aimed to review the existing literature on the different types of neutralization assays and
international standards for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
international standards for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant
Antibody responses against the SARS-CoV-2 Spike protein correlate with protection against
COVID-19. Serum neutralizing antibodies appear early after symptom onset following SARS …
COVID-19. Serum neutralizing antibodies appear early after symptom onset following SARS …
Advances in neutralization assays for SARS‐CoV‐2
Y Lu, J Wang, Q Li, H Hu, J Lu… - Scandinavian Journal of …, 2021 - Wiley Online Library
Abstract The coronavirus disease 2019 (COVID‐19) pandemic has triggered a global health
emergency and brought disaster to humans. Tremendous efforts have been made to control …
emergency and brought disaster to humans. Tremendous efforts have been made to control …
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough …
MI Azeem, AK Nooka, U Shanmugasundaram… - Blood cancer …, 2023 - AACR
Patients with multiple myeloma (MM) mount suboptimal neutralizing antibodies (nAb)
following 2 doses of SARS-CoV-2 mRNA vaccines. Currently, circulating SARS-CoV-2 …
following 2 doses of SARS-CoV-2 mRNA vaccines. Currently, circulating SARS-CoV-2 …
ACE2 N-glycosylation modulates interactions with SARS-CoV-2 spike protein in a site-specific manner
A Isobe, Y Arai, D Kuroda, N Okumura, T Ono… - Communications …, 2022 - nature.com
SARS-CoV-2 has evolved continuously and accumulated spike mutations with each variant
having a different binding for the cellular ACE2 receptor. It is not known whether the …
having a different binding for the cellular ACE2 receptor. It is not known whether the …
AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans
Vaccine adjuvants increase the breadth of serum antibody responses, but whether this is
due to the generation of antigen-specific B cell clones with distinct specificities or the …
due to the generation of antigen-specific B cell clones with distinct specificities or the …
Durability of immune responses to the BNT162b2 mRNA vaccine
Durability of immune responses to the BNT162b2 mRNA vaccine: Med Skip to Main Content
Advertisement Med This journal offers authors two options (open access or subscription) to …
Advertisement Med This journal offers authors two options (open access or subscription) to …
Immune correlates of protection by mRNA-1273 immunization against SARS-CoV-2 infection in nonhuman primates
Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy.
The nonhuman primate (NHP) model of SARS-CoV-2 infection replicates key features of …
The nonhuman primate (NHP) model of SARS-CoV-2 infection replicates key features of …